Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 14, 2026

Wells Fargo retains $50B 2026 net interest income outlook as Basel proposal implies ~7% RWA decline

View original at seekingalpha.com
Wells Fargo retains $50B 2026 net interest income outlook as Basel proposal implies ~7% RWA decline Earnings Call Insights: Wells Fargo & Company (WFC) Q1 2026 MANAGEMENT VIEW * "We saw continued positive impacts from the investments we've been making with diluted earnings per share increasing 15%, revenue increasing 6…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wells Fargo feels confident the fraud-related loss in financials-ex-banks was an isolated event

    60% confidence
  • There's no magic to 10% to 10.5% in the future if capital requirements change

    60% confidence
  • Period-end loan balances grew 11% from a year ago and exceeded $1 trillion for the first time since Q1 2020

    60% confidence
  • Wells Fargo is actually really confident in the path to 17%-18% ROTCE

    60% confidence
  • Wells Fargo still expects 2026 noninterest expense to be approximately $55.7 billion

    60% confidence
  • Wells Fargo returned $5.4 billion to shareholders in Q1, including $4 billion in common stock repurchases, while continuing to operate with significant excess capital

    60% confidence
  • Markets balance-sheet growth shouldn't be dilutive to ROTCE, and Wells Fargo will either get increased flows at strong ROTCE or won't use the balance sheet for it

    60% confidence
  • Three things drove NIM compression: markets balance-sheet mix, interest-bearing deposit mix, and rates coming off the back of Q4

    60% confidence
  • Wells Fargo closed its final outstanding consent order last month, bringing total to 14 terminated since 2019 and is now focusing more fully on accelerating growth and improving returns

    60% confidence
  • Expectation of approximately $2 billion in 2026 seems appropriate

    60% confidence
  • Wells Fargo is not reacting today to concerns about NBFI lending and disclosures aim to ensure investors feel as good about what they're doing as management does

    60% confidence
  • Wells Fargo is still going to stick with the 10%-10.5% CET1 target

    60% confidence
  • Card growth is about awareness and advertising

    60% confidence
  • At the end of Q1, financials except bank loans totaled approximately $210 billion, or 21% of total loan portfolio

    60% confidence
  • Wells Fargo's outlook assumed 2-3 cuts by the Federal Reserve, but the market currently expects fewer cuts

    60% confidence
  • Wells Fargo's CET1 ratio of 10.3% is within stated 10% to 10.5% target range

    60% confidence
  • Noninterest expense increased $439 million, or 3% from a year ago and included approximately $700 million of seasonally higher expenses

    60% confidence
  • Noninterest income increased $696 million, or 8% from a year ago

    60% confidence
  • Under Basel proposal, operational risk will increase but there's a big decline on credit risk with benefits for investment-grade credits and mortgage portfolio, leading to about 7% decline overall in RWA

    60% confidence
  • Debt markets are wide open and IPOs may return if volatility stabilizes

    60% confidence
  • Rates are driving NII pressure and Wells Fargo is not competing on price to grow the balance sheet

    60% confidence
  • Wells Fargo saw diluted earnings per share increase 15%, revenue increase 6%, loans grow 11% and deposits up 7% compared to a year ago

    60% confidence
  • Wells Fargo is retaining guidance of $50 billion, plus or minus, of net interest income for 2026

    60% confidence
  • Under the proposed Basel capital rules, Wells Fargo's risk-weighted assets could decrease by approximately 7%

    60% confidence
  • Expects additional margin compression next quarter

    60% confidence
  • Wells Fargo's net loan charge-off ratio was stable from a year ago and commercial losses included a single fraud-related loss believed to be an isolated incident

    60% confidence
  • Net interest income increased $601 million, or 5% from a year ago, and decreased $235 million, or 2% from Q4

    60% confidence
  • There is absolutely nothing that has changed regarding ROTCE targets

    60% confidence
  • Card account growth is driven by really good, compelling, simple products

    60% confidence
  • Private credit sizing in corporate debt finance bucket is about $36.2 billion

    60% confidence

Data points we hold from this source

Wells Fargo & Company · tax benefit135 USD
Wells Fargo & Company · noninterest income yoy growth8 percent
Wells Fargo & Company · share repurchases4 USD
Wells Fargo & Company · tax benefit per share0.04 USD
Wells Fargo & Company · deposit growth7 percent
Wells Fargo & Company · net interest income qoq growth-2 percent
Wells Fargo & Company · private credit exposure36.2 USD
Wells Fargo & Company · consent orders terminated since 201914 count
Wells Fargo & Company · shareholder return5.4 USD
Wells Fargo & Company · net interest income yoy change601 USD
Wells Fargo & Company · seasonal expense increase700 USD
Wells Fargo & Company · loan growth11 percent
Wells Fargo & Company · noninterest income yoy change696 USD
Wells Fargo & Company · total loans1000 USD
Wells Fargo & Company · net interest income yoy growth5 percent
Wells Fargo & Company · noninterest expense yoy change439 USD
Wells Fargo & Company · financials except bank loans percentage21 percent
Wells Fargo & Company · cet1 ratio10.3 percent
Wells Fargo & Company · financials except bank loans210 USD
Wells Fargo & Company · noninterest expense yoy growth3 percent
Wells Fargo & Company · net interest income qoq change-235 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com